Dr. Evan Yu presents the new evidence-based guideline on genetic testing for metastatic prostate cancer. He discusses who should receive germline and somatic testing with next-generation sequencing ...

More evidence points to the benefits of germline genetic testing for patients with various cancers. Such testing can identify mutations that may warrant a change of treatment and allow trying a ...

Mutations in BRCA1 do not appear to contribute significantly to the risk of prostate cancer progression, according to DNA test results from 450 prostate cancer specimens. The findings suggest that ...

Genetic testing, including germline and somatic, is vital for prostate cancer prognosis and personalized treatment strategies. PARP inhibitors, targeting BRCA mutations, are a promising therapy for ...

From 7% to nearly 9% of patients with advanced cancer were found to harbor a germline variant with targeted therapeutic actionability in the first study of its kind. The study involved 11,974 patients ...

Mutations in the BRCA1 gene that are either inherited (germline) or acquired (somatic) might not be key to the initiation of prostate cancer, as previously thought, suggests the first study of its ...

Mutations in the BRCA1 gene that are either inherited (germline) or acquired (somatic) might not be key to the initiation of prostate cancer, as previously thought, suggests the first study of its ...

Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials ASCO Guidelines provide recommendations with comprehensive ...